AC Immune SA Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.60next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Reserves (CHF) Quarterly74.8MTarget: Sufficient capital to fund operations into Q4 2027
ABATE Phase 1b/2 Trial Cohort Enrollment (ACI-24.060) Quarterly4.0Target: Complete evaluation of Cohort AD4 and report 12-month interim data for Cohorts AD1-AD3
VacSYn Phase 2 Trial Progress (ACI-7104.056) Annually1.0Target: Report full data from Part 1 of the trial in H2 2026
Watch Items
- ACI-7104.056 VacSYn Phase 2 Part 1 Full Data ReadoutTrigger: H2 2026 publication of safety, immunogenicity, and clinical efficacy signalsAction: Evaluate disease-modifying potential in early Parkinson's disease and assess long-term development strategy
- Takeda Option Exercise on ACI-24.060Trigger: Decision by Takeda to exercise its option following clinical data milestonesAction: Prepare for transition of late-stage development and commercialization responsibilities to Takeda and secure low-to-mid nine-figure option fee
- CEO Transition and Leadership StabilityTrigger: Retirement of long-tenured CEO Dr. Andrea Pfeifer announced at the June 2026 AGMAction: Monitor the appointment and onboarding of the successor CEO to ensure strategic continuity
Research as of 20 Jun 2026